Table 1. Summary of the in vitro and in... | American Society of Hematology

Table 1.

Summary of the in vitro and in vivo mAb activities

			In vitro	In vivo
mAbs	Immunogen	ECD	Permeability, IC₅₀ μg/mL	Angiogenesis, % inhibition	Vascular permeability, % increase	Maximum tolerable dose, mg
E4G10	15mer peptide	1	2-6	78 ± 25	< 25	> 10
BV13	smVEC-Fc	1	1-3	72 ± 14	> 200	< 0.1
10G4	smVEC-Fc	1	1-3	89 ± 28	> 200	< 0.1
13E6	smVEC-Fc	2	> 100	< 15	< 25	> 5
8A7	smVEC-Fc	3	> 100	< 15	< 25	> 5
15F12	smVEC-Fc	4	> 100	< 15	< 25	> 5
2B11	smVEC-Fc	5	> 100	ND	ND	> 5

			In vitro	In vivo
mAbs	Immunogen	ECD	Permeability, IC₅₀ μg/mL	Angiogenesis, % inhibition	Vascular permeability, % increase	Maximum tolerable dose, mg
E4G10	15mer peptide	1	2-6	78 ± 25	< 25	> 10
BV13	smVEC-Fc	1	1-3	72 ± 14	> 200	< 0.1
10G4	smVEC-Fc	1	1-3	89 ± 28	> 200	< 0.1
13E6	smVEC-Fc	2	> 100	< 15	< 25	> 5
8A7	smVEC-Fc	3	> 100	< 15	< 25	> 5
15F12	smVEC-Fc	4	> 100	< 15	< 25	> 5
2B11	smVEC-Fc	5	> 100	ND	ND	> 5

SmVEC-Fc indicates soluble murine VE-cadherin-Fc; ND, not determined.